ideaya: Precision medicine company that develops targeted medications, specializing in therapeutics for cancer patients.
For PARP inhibitors, diagnostic tools have already been introduced that quantify genomic signatures indicative of PARP inhibitor sensitivity. Bob is Vice President of Manufacturing and offer and Head of CMC at Zentalis Pharmaceuticals. He brings over 30 years of international pharmaceutical and biopharmaceutical experience in the design, implementation and operation of global supply chains for…